Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM89NIB)

Drug Name

UX143 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Osteogenesis imperfecta	LD24.K0	Phase 3	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Sclerostin (SOST)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Romosozumab	DMFJZN0	Postmenopausal osteoporosis	FB83.11	Approved	[3]
LY2541546	DMTVU2Q	Osteoporosis	FB83.0	Phase 2	[4]
BPS-804	DMDYZRS	Metabolic bone disease	FB8Y	Phase 2	[5]
AMG 167	DMUETI2	Osteoporosis	FB83.0	Phase 1	[6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	ClinicalTrials.gov (NCT05768854) An Open-label, Randomized, Active-Controlled, Phase 3 Study of Setrusumab Compared With Bisphosphonates in Pediatric Subjects With Osteogenesis Imperfecta Types I, III or IV. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Ultragenyx Pharmaceutical
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94.
5	WO patent application no. 2010,1001,79, Self-forming gel system for sustained drug delivery.
6	Osteoporosis - a current view of pharmacological prevention and treatment. Drug Des Devel Ther. 2013; 7: 435-448.